Helen Louise Collins, Chief Medical Officer: Enliven Therapeutics ELVN Sell · Filed 06/22

Trade details

Type: Insider sale
Amount: $114,018.13
Shares · price: 2,599 sh · $43.87 a share
Held after: 26,133 sh
Stock: Enliven Therapeutics ELVN
Person: Helen Louise CollinsChief Medical Officer
Trade date: 26/06/17
Filed: 26/06/22
Days to filing: 5 days

Sold 9.0% of holdings

Share of holding sold: 9.0%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 05/18~07/17

Helen Louise Collins's recent trades

Helen Louise CollinsChief Medical Officer
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$762.9K
15,000 sh
$762.9K
Filed 07/17
Traded 07/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$54.3K
1,268 sh
$54.3K
Filed 06/22
Traded 06/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$50.7K
1,133 sh
$50.7K
Filed 06/22
Traded 06/17
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$137.4K
3,475 sh
$137.4K
Filed 05/20
Traded 05/18
Helen Louise CollinsChief Medical Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$52.4K
1,302 sh
$52.4K
Filed 05/20
Traded 05/18

Helen Louise Collins, Chief Officer — sold $114K of Enliven Therapeutics ELVN · 9.0% of holdings · 10b5-1 plan | Whalegun